{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444260047
| ImageFile =Quizartinib.svg
| ImageSize =
| ImageAlt =
| IUPACName =1-(5-(''tert''-Butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[''d'']imidazo[2,1-b]thiazol-2-yl)phenyl)urea
| OtherNames = AC220
| Section1 = {{Chembox Identifiers
| IUPHAR_ligand = 5658
| CASNo =950769-58-1
| CASNo_Ref = {{cascite|correct|??}}
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 90217
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 576982
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 24640357
| KEGG = D09955
| SMILES = CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6
| InChI = 1/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
| InChIKey = CVWXJKQAOSCOAB-UHFFFAOYAF
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = CVWXJKQAOSCOAB-UHFFFAOYSA-N
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7LA4O6Q0D3
  }}
| Section2 = {{Chembox Properties
| C=29 |H=32 |N=6 |O=4 |S=1
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility =
  }}
| Section3 = {{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
  }}
| Section5 = {{Chembox Pharmacology
| AdminRoutes =
| Bioavail =
| Metabolism =
| HalfLife =
| ProteinBound =
| Excretion =
| Legal_status =
| Legal_US =
| Legal_UK =
| Legal_AU =
| Legal_CA =
| PregCat =
| PregCat_AU =
| PregCat_US =
  }}
}}

'''Quizartinib''' (AC220) is a small molecule [[receptor tyrosine kinase]] inhibitor that is currently under development by [[Ambit Biosciences]] for the treatment of [[acute myeloid leukaemia]]. Its molecular target is [[FLT3]], also known as CD135 which is a [[proto-oncogene]].<ref>{{cite journal |author1=Chao, Qi |author2=Sprankle, Kelly G. |author3=Grotzfeld, Robert M. |author4=Lai, Andiliy G. |author5=Carter, Todd A. |author6=Velasco, Anne Marie |author7=Gunawardane, Ruwanthi N. |author8=Cramer, Merryl D. |author9=Gardner, Michael F. |author10=James, Joyce |author11=Zarrinkar, Patrick P. |author12=Patel, Hitesh K. |author13=Bhagwat, Shripad S. | title = Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N'-<nowiki/>{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor | journal = Journal of Medicinal Chemistry | year = 2009 | volume = 52 | issue = 23 | pages = 7808â€“7816 | doi=10.1021/jm9007533}}</ref>

Flt3 mutations are among the most common mutations in [[acute myeloid leukaemia]] due to [[internal tandem duplication]] of Flt3. The presence of this mutation is a marker of adverse outcome.

==Mechanism==
Specifically, Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 ([[FLT3]]/STK1), colony-stimulating factor 1 receptor ([[CSF1R]]/[[FMS (gene)|FMS]]), [[stem cell factor receptor]] (SCFR/[[KIT (gene)|KIT]]), and platelet derived growth factor receptors ([[PDGFR]]s).{{citation needed|date=December 2012}}

Mutations cause constitutive action of Flt3 resulting in inhibition of [[ligand-independent leukemic cell proliferation]] and apoptosis.{{citation needed|date=December 2012}}

==Clinical trials==
It reported good results in 2012 from a phase II clinical trial for refractory AML - particularly in patients who went on to have a stem cell transplant.<ref name=ASH2012>[http://www.medpagetoday.com/MeetingCoverage/ASHHematology/36351 Drug Tames Refractory AML. ASH Dec 2012]</ref>

{{as of|2017}} it has completed 5 clinical trials and another 7 are active.<ref>[https://clinicaltrials.gov/ct2/results?term=quizartinib&Search=Search Quizartinib studies]</ref>

==References==
{{Reflist}}


{{Cytokine receptor modulators}}
{{Growth factor receptor modulators}}

[[Category:Receptor tyrosine kinase inhibitors]]
[[Category:Morpholines]]
[[Category:Isoxazoles]]
[[Category:Ureas]]
[[Category:Tert-butyl compounds]]